Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a studyVolkan Granit, Matthew T. Duvernay, Naraly Requena et al.|The Lancet Neurology|2023Cited by 255
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALSMichael Benatar, G. Garcia Gutierrez, Lanyu Zhang et al.|Neurology|2020Cited by 201
Towards a neuroimaging biomarker for amyotrophic lateral sclerosisMartin R. Turner, Bahram Mohammadi, Julian Großkreutz et al.|The Lancet Neurology|2011Cited by 167
Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseasesMichael Benatar, Joanne Wuu, Caroline McHutchison et al.|Brain|2021Cited by 116
Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entityMichael Benatar, Joanne Wuu, Volkan Granit et al.|Brain|2022Cited by 57